Asou N, Nishikawa K, Suzushima H, Takatsuki K
Second Department of Internal Medicine, Kumamoto University Medical School.
Nihon Rinsho. 1992 Jun;50(6):1400-6.
Expression of multidrug resistance (mdr 1) gene, which encodes a transmembrane efflux pump referred to P-glycoprotein, leads to the decreased intracellular accumulation of various lipophilic drugs, such as vinca alkaloids, anthracyclines and epipodophyllotoxins. As these drugs are commonly used in chemotherapy for acute leukemia, it is of importance to determine whether mdr 1/P-glycoprotein expression is associated with clinical resistance. In several reports, some leukemia cells from untreated patients have expression of mdr 1/P-glycoprotein. We quantitatively detected low levels of mdr 1 expression in all cases of untreated acute leukemia and normal hematopoietic cells, using the reverse transcriptase-polymerase chain reaction. Carefully designed clinical trials including mdr 1 reversing agents may have significant consequences for the treatment of acute leukemia.
多药耐药(mdr 1)基因编码一种称为P - 糖蛋白的跨膜外排泵,其表达会导致多种亲脂性药物(如长春花生物碱、蒽环类药物和表鬼臼毒素)在细胞内的积累减少。由于这些药物常用于急性白血病的化疗,因此确定mdr 1/P - 糖蛋白表达是否与临床耐药相关至关重要。在一些报告中,未经治疗患者的一些白血病细胞有mdr 1/P - 糖蛋白的表达。我们使用逆转录聚合酶链反应定量检测了所有未经治疗的急性白血病病例和正常造血细胞中低水平的mdr 1表达。精心设计的包含mdr 1逆转剂的临床试验可能会对急性白血病的治疗产生重大影响。